 | Up a level |
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; ... (2024). Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. (In Press). The lancet Elsevier 10.1016/S0140-6736(24)00184-3
Zucca, Emanuele; Davies, Andrew; Kryachok, Irina; Ciccone, Giovannino; Ceriani, Luca; Botto, Barbara; Mikhaeel, N. George; Dabrowska-Iwanicka, Anna; Zhao, Weili; Ionescu, Codruta; Janikova, Andrea; Fossa, Alexander; Hodgson, David; Jerkeman, Mats; Balzarotti, Monica; Tucci, Alessandra; Ricardi, Umberto; Barrington, Sally; Johnson, Peter W. M. and Martelli, Maurizio (10 June 2023). Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial. Journal of clinical oncology, 41(17_suppl), LBA7505-LBA7505. American Society of Clinical Oncology 10.1200/JCO.2023.41.17_suppl.LBA7505
